SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-19-026623
Filing Date
2019-05-15
Accepted
2019-05-15 16:42:14
Documents
72
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tv520717_10q.htm 10-Q 544364
2 EXHIBIT 10.1 tv520717_ex10-1.htm EX-10.1 576525
3 EXHIBIT 31.1 tv520717_ex31-1.htm EX-31.1 8084
4 EXHIBIT 32.1 tv520717_ex32-1.htm EX-32.1 4364
  Complete submission text file 0001144204-19-026623.txt   4934590

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT ons-20190331.xml EX-101.INS 745057
6 XBRL TAXONOMY EXTENSION SCHEMA ons-20190331.xsd EX-101.SCH 57658
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ons-20190331_cal.xml EX-101.CAL 36714
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ons-20190331_def.xml EX-101.DEF 250338
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ons-20190331_lab.xml EX-101.LAB 499256
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ons-20190331_pre.xml EX-101.PRE 375738
Mailing Address 7 CLARKE DRIVE CRANBURY NJ 08512
Business Address 7 CLARKE DRIVE CRANBURY NJ 08512 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 19829046
SIC: 2836 Biological Products, (No Diagnostic Substances)